These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 14646680)

  • 1. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma.
    Camras CB; Hedman K;
    J Glaucoma; 2003 Dec; 12(6):466-9. PubMed ID: 14646680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
    Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
    Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials.
    Fechtner RD; Airaksinen PJ; Getson AJ; Lines CR; Adamsons IA;
    Acta Ophthalmol Scand; 2004 Feb; 82(1):42-8. PubMed ID: 14982045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-Hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial.
    Walters TR; DuBiner HB; Carpenter SP; Khan B; VanDenburgh AM;
    Surv Ophthalmol; 2004 Mar; 49 Suppl 1():S26-35. PubMed ID: 15016559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
    Varma R; Hwang LJ; Grunden JW; Bean GW
    Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
    Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
    J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of latanoprost with fixed-combination dorzolamide and timolol in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label, parallel-group, multicenter study in Latin America.
    Susanna R; Sheu WP;
    Clin Ther; 2004 May; 26(5):755-68. PubMed ID: 15220019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Efficacy of a Latanoprost/Timolol Fixed Combination Versus Latanoprost and Timolol Gel-forming Solution Unfixed Combination on Daytime Intraocular Pressure.
    Özyol E; Özyol P
    J Glaucoma; 2016 Feb; 25(2):135-9. PubMed ID: 25264990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish Latanoprost Study Group.
    Nordmann JP; Söderström M; Rouland JF; Malecaze F
    Br J Ophthalmol; 2000 Feb; 84(2):181-5. PubMed ID: 10655195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pooled-data analysis of three randomized, double-masked, six-month studies comparing intraocular pressure-reducing effects of latanoprost and timolol in patients with ocular hypertension.
    Hedman K; Alm A; Gross RL
    J Glaucoma; 2003 Dec; 12(6):463-5. PubMed ID: 14646679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece.
    Petounis A; Mylopoulos N; Kandarakis A; Andreanos D; Dimitrakoulias N
    J Glaucoma; 2001 Aug; 10(4):316-24. PubMed ID: 11558817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
    Diestelhorst M; Larsson LI;
    Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol.
    Hedman K; Alm A
    Eur J Ophthalmol; 2000; 10(2):95-104. PubMed ID: 10887918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Netland PA; Landry T; Sullivan EK; Andrew R; Silver L; Weiner A; Mallick S; Dickerson J; Bergamini MV; Robertson SM; Davis AA;
    Am J Ophthalmol; 2001 Oct; 132(4):472-84. PubMed ID: 11589866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
    Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
    Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.